Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.

Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Abraham J, Thomas J, Provenzano E, Hughes-Davies L, Gounaris I, McAdam K, Chan S, Ahmad R, Hickish T, Houston S, Rea D, Bartlett J, Caldas C, Cameron DA, Hayward L; ARTemis Investigators..

Lancet Oncol. 2015 Jun;16(6):656-66. doi: 10.1016/S1470-2045(15)70137-3. Epub 2015 May 11.

2.

Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.

Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM; PRIME II investigators..

Lancet Oncol. 2015 Mar;16(3):266-73. doi: 10.1016/S1470-2045(14)71221-5. Epub 2015 Jan 28. Erratum in: Lancet Oncol. 2015 Mar;16(3):e105.

PMID:
25637340
3.

Insufficiency fractures in patients treated with pelvic radiotherapy and chemotherapy for uterine and cervical cancer.

Mehmood Q, Beardwood M, Swindell R, Greenhalgh S, Wareham T, Barraclough L, Livsey J, Davidson SE.

Eur J Cancer Care (Engl). 2014 Jan;23(1):43-50. doi: 10.1111/ecc.12105. Epub 2013 Jul 25.

PMID:
23889218
4.

The case for including bowel urgency in toxicity reporting after pelvic cancer treatment.

Henson CC, Anandadas CN, Barraclough LH, Swindell R, West CM, Davidson SE.

J Natl Compr Canc Netw. 2013 Jul;11(7):827-33.

PMID:
23847219
5.

Prospective analysis of patient-reported late toxicity following pelvic radiotherapy for gynaecological cancer.

Barraclough LH, Routledge JA, Farnell DJ, Burns MP, Swindell R, Livsey JE, Davidson SE.

Radiother Oncol. 2012 Jun;103(3):327-32. doi: 10.1016/j.radonc.2012.04.018. Epub 2012 May 23.

PMID:
22633812
6.

Breast-cancer adjuvant therapy with zoledronic acid.

Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R; AZURE Investigators..

N Engl J Med. 2011 Oct 13;365(15):1396-405. doi: 10.1056/NEJMoa1105195. Epub 2011 Sep 25.

7.

Efficacy of data capture for patient-reported toxicity following radiotherapy for prostate or cervical cancer.

Farnell DJ, Routledge J, Hannon R, Logue JP, Cowan RA, Wylie JP, Barraclough LH, Livsey JE, Swindell R, Davidson SE.

Eur J Cancer. 2010 Feb;46(3):534-40. doi: 10.1016/j.ejca.2009.11.017. Epub 2009 Dec 21.

PMID:
20022742
8.

Early laparoscopic cholecystectomy service provision is feasible and safe in the current UK National Health Service.

Agrawal S, Battula N, Barraclough L, Durkin D, Cheruvu CV.

Ann R Coll Surg Engl. 2009 Nov;91(8):660-4. doi: 10.1308/003588409X464478. Epub 2009 Aug 14.

9.

Estimation of renal function -- what is appropriate in cancer patients?

Barraclough LH, Field C, Wieringa G, Swindell R, Livsey JE, Davidson SE.

Clin Oncol (R Coll Radiol). 2008 Dec;20(10):721-6. doi: 10.1016/j.clon.2008.09.004.

PMID:
18995170
10.

External beam boost for cancer of the cervix uteri when intracavitary therapy cannot be performed.

Barraclough LH, Swindell R, Livsey JE, Hunter RD, Davidson SE.

Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):772-8. doi: 10.1016/j.ijrobp.2007.10.066. Epub 2008 Jan 22.

PMID:
18207658
11.

Effect of gravito-inertial cues on the coding of orientation in pre-attentive vision.

Stivalet P, Marendaz C, Barraclough L, Mourareau C.

J Vestib Res. 1995 Mar-Apr;5(2):125-35.

PMID:
7743002
12.

Effect of gravitational cues on visual search for orientation.

Marendaz C, Stivalet P, Barraclough L, Walkowiac P.

J Exp Psychol Hum Percept Perform. 1993 Dec;19(6):1266-77.

PMID:
8294891

Supplemental Content

Loading ...
Support Center